Just one week after Vermont Sen. Bernie Sanders sent a scathing letter to Catalyst Pharmaceuticals CEO questioning his plans to charge $375,000 for its rare-disease drug Firdapse, the company said it's sticking to that number.
Just one week after Vermont Sen. Bernie Sanders sent a scathing letter to Catalyst Pharmaceuticals CEO questioning his plans to charge $375,000 for its rare-disease drug Firdapse, the company said it's sticking to that number.
The controversy over rising drug prices in the US has been reignited after it emerged that the yearly cost of the life-sustaining rare disease drug Firdapse has been hiked from free to more than $300,000.